Oruka Therapeutics (ORKA) Assets (2010 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Assets of $504.5 million for Q1 2026, up 33.77% year-over-year from $377.1 million in Q1 2025, and up 3.25% quarter-over-quarter from $488.6 million in Q4 2025.
Oruka Therapeutics (ORKA) Assets (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Assets history runs 17 years deep, the most recent figure standing at $504.5 million for Q1 2026.
- In Q1 2026, Assets rose 33.77% year-over-year to $504.5 million; the TTM figure through Mar 2026 stood at $504.5 million (up 33.77% YoY), while the FY2025 annual figure was $488.6 million, up 23.38% from the prior year.
- Assets for Q1 2026 stood at $504.5 million, up from $488.6 million in the prior quarter.
- The five-year high for Assets was $509.3 million in Q3 2025, with the low at $33.8 million in Q2 2024.
- The 5-year median for Assets is $48.1 million (2022), against an average of $203.8 million.
- The sharpest annual moves came in 2022 and 2024: Assets retreated 26.38% in 2022, then soared 956.78% in 2024.
- Oruka Therapeutics' Assets stood at $43.1 million in 2022, then fell by 12.12% to $37.9 million in 2023, then soared by 945.98% to $396.0 million in 2024, then advanced by 23.38% to $488.6 million in 2025, then gained by 3.25% to $504.5 million in 2026.
- Business Quant data shows ORKA's Assets at $504.5 million in Q1 2026, $488.6 million in Q4 2025, and $509.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | 1.14 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Bn |
| Mar 31, 2026 | 504.48 Mn |
| Dec 31, 2025 | 488.62 Mn |
| Sep 30, 2025 | 509.25 Mn |
| Jun 30, 2025 | 357.42 Mn |
| Mar 31, 2025 | 377.11 Mn |
| Dec 31, 2024 | 396.02 Mn |
| Sep 30, 2024 | 414.09 Mn |
| Jun 30, 2024 | 33.84 Mn |
| Mar 31, 2024 | 36.71 Mn |
| Dec 31, 2023 | 37.86 Mn |
| Sep 30, 2023 | 39.18 Mn |
| Jun 30, 2023 | 41.08 Mn |
| Mar 31, 2023 | 42.06 Mn |
| Dec 31, 2022 | 43.09 Mn |
| Sep 30, 2022 | 44.97 Mn |
| Jun 30, 2022 | 48.10 Mn |
| Mar 31, 2022 | 51.01 Mn |
| Dec 31, 2021 | 54.92 Mn |
| Sep 30, 2021 | 60.19 Mn |